The Columbia University Medical Center/Weill Cornell Medical Center NEXT site has been selected to participate in the first NeuroNEXT clinical trial. The site Principal Investigator of the Spinal Muscular Atrophy (SMA) Biomarker in the Immediate Postnatal Period of Development" is Claudia A. Chiriboga, MD, MPH. Dr. Chiriboga is Associate Professor of Clinical Neurology and Pediatrics and acting Director and Program Director of Division of Pediatric Neurology at Columbia University College of Physicians and Surgeons, as well as member of the SMA Clinical Research Center of Columbia University. Dr. Chiriboga's clinical research experience has included NIH funded cohort studies of congenital infections and neurodevelopmental disorders, such as cerebral palsy and effects of perinatal exposures. Dr. Chiriboga's clinical trials experience includes trials in periodontal exposure effects, metabolic disorders and SMA.
Fifty-four research subjects are currently being recruited for the 'Spinal Muscular Atrophy (SMA) Biomarker in the Immediate Postnatal Period of Development' study at approximately 15 centers nationwide. This study is looking for infants up to 6 months of age that have been diagnosed with SMA, and also healthy infants for a control group. This study aims to identify ways to measure how SMA affects children, and whether they are getting better, worse or staying the same.
Interested subjects should contact the SMA Biomarker Study Team:
1-855-SMA-BIOM or 1-855-762-2466